SBL
NKTR icon

Sargent Bickham Lagudis’s Nektar Therapeutics NKTR Stock Holding History

Sargent Bickham Lagudis’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6
Closed -$6K – 777
2018
Q3 		$6K Hold
6
– – ﹤0.01% 673
2018
Q2 		$5K Buy
+6
New +$6.92K ﹤0.01% 668

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sargent Bickham Lagudis's NKTR Position: Q4 2018 in Review

Sargent Bickham Lagudis sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 6 shares — an estimated $6K sold.

Sargent Bickham Lagudis first reported a position in NKTR in Q2 2018 and held it in 2 quarters. The position peaked at $6K in Q3 2018. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Sargent Bickham Lagudis reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 6 Nektar Therapeutics shares in Q4 2018, an estimated $6K.
  • Sargent Bickham Lagudis first reported a position in Nektar Therapeutics in Q2 2018 and held it in 2 quarters.
  • Sargent Bickham Lagudis's Nektar Therapeutics position peaked at $6K in Q3 2018.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2018, filed 13 Sep 2021.